Real-world data shows drugs’ benefits at ASH 2019
- Eliquis, Adynovate and Feiba were presented in last month’s ASH 2019 meeting as the subject of studies which showed their benefits through the use of real-world data.
- Results focused on cost-effectiveness, safety, outcomes and benefits.
- “Real-world evidence plays a crucial role in understanding patterns of care that happen in day-to-day medical practice outside of rigorous clinical studies,” Jonathan Roberts, MD, Bleeding & Clotting Disorders Institute.
- “Real-world evidence analyses such as this have the potential to provide additional insights into complex patient populations such as those with VTE and active cancer,” said Alexander Cohen, MD, Consultant Physician, Department of Hematology at Guy’s and St. Thomas’ NHS Foundation Trust.
SVMPharma is an innovative strategic consultancy, specialising in Real World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.